These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31833634)

  • 21. More Than Just Wait Time? Regional Differences in Liver Transplant Outcomes for Hepatocellular Carcinoma.
    Hogen R; Lo M; DiNorcia J; Ji L; Genyk Y; Sher L; Dhanireddy K
    Transplantation; 2019 Apr; 103(4):747-754. PubMed ID: 29672442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".
    Mehta N; Heimbach J; Lee D; Dodge JL; Harnois D; Burns J; Sanchez W; Roberts JP; Yao FY
    Transplantation; 2017 Sep; 101(9):2071-2078. PubMed ID: 28353492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are hepatocellular carcinoma patients more likely to receive liver resection in regions with longer transplant wait times?
    Anderson JE; Hemming AW; Chang DC; Talamini MA; Mekeel KL
    Transplant Proc; 2014; 46(1):199-201. PubMed ID: 24507051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.
    Kwong AJ; Lai JC; Dodge JL; Roberts JP
    Liver Transpl; 2015 Nov; 21(11):1403-9. PubMed ID: 26289624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma.
    Cullaro G; Rubin JB; Mehta N; Lai JC
    Liver Transpl; 2020 Mar; 26(3):349-358. PubMed ID: 31610089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post-transplantation.
    Patel MS; Kohn R; Kratz JR; Shah JA; Markmann JF; Vagefi PA
    J Am Coll Surg; 2015 Jun; 220(6):1001-7. PubMed ID: 25868408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
    Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
    Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis.
    Lee MW; Raman SS; Asvadi NH; Siripongsakun S; Hicks RM; Chen J; Worakitsitisatorn A; McWilliams J; Tong MJ; Finn RS; Agopian VG; Busuttil RW; Lu DSK
    Hepatology; 2017 Jun; 65(6):1979-1990. PubMed ID: 28170115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. National experience with living donor liver transplantation for hepatocellular carcinoma.
    Silverstein J; Yao FY; Grab JD; Braun HJ; Roberts J; Dodge JL; Mehta N
    Liver Transpl; 2022 Jul; 28(7):1144-1157. PubMed ID: 35226793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation.
    Samoylova ML; Dodge JL; Yao FY; Roberts JP
    Liver Transpl; 2014 Aug; 20(8):937-44. PubMed ID: 24797145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence.
    Piñero F; Boin I; Chagas A; Quiñonez E; Marciano S; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Mendizabal M; Hurtado Gomez S; Stucchi R; Maccali C; Vergara Sandoval R; Bermudez C; McCormack L; Varón A; Gadano A; Mattera J; Rubinstein F; Carrilho F; Silva M
    Liver Transpl; 2020 May; 26(5):640-650. PubMed ID: 32133773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
    Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
    Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
    Lee DD; Samoylova M; Mehta N; Musto KR; Roberts JP; Yao FY; Harnois DM
    Liver Transpl; 2019 Feb; 25(2):228-241. PubMed ID: 30198150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Definitive locoregional therapy (LRT) versus bridging LRT and liver transplantation with wait-and-not-treat approach for very early stage hepatocellular carcinoma.
    Habibollahi P; Hunt S; Bitterman T; Gade TP; Soulen MC; Nadolski G
    Diagn Interv Radiol; 2018 Jul; 24(4):213-218. PubMed ID: 30091712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MELD EXCEPTION POINTS PROVIDE AN ENOURMOUS ADVANTAGE FOR RECEIVING A LIVER TRANSPLANT IN BRAZIL.
    Arruda S; Chedid MF; Jacinto MM; Álvares-DA-Silva MR
    Arq Gastroenterol; 2020; 57(3):254-261. PubMed ID: 32935744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Would a 6-Month Wait Time for Patients With Hepatocellular Carcinoma Improve Organ Allocation in Centers With Active Living Related Liver Transplant Activity?
    Shaheen MF; Alomar A; Alrasheed M; Aldokhel F; Alsaleh A; Alghamdi H; O'hali W; Bin Saad K
    Exp Clin Transplant; 2023 Feb; 21(2):132-138. PubMed ID: 36919721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous Risk Score Predicts Waitlist and Post-transplant Outcomes in Hepatocellular Carcinoma Despite Exception Changes.
    Akabane M; McVey JC; Firl DJ; Kwong AJ; Melcher ML; Kim WR; Sasaki K
    Clin Gastroenterol Hepatol; 2024 Oct; 22(10):2044-2052.e4. PubMed ID: 38908731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HEPATOCELLULAR CARCINOMA PATIENTS ARE ADVANTAGED IN THE CURRENT BRAZILIAN LIVER TRANSPLANT ALLOCATION SYSTEM. A COMPETING RISK ANALYSIS.
    Rodríguez S; Fleck AM; Mucenic M; Marroni C; Brandão A
    Arq Gastroenterol; 2020; 57(1):19-23. PubMed ID: 32294731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States.
    Shah RH; Chyou D; Goldberg DS
    Liver Transpl; 2022 Dec; 28(12):1857-1864. PubMed ID: 35585774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.